阿迪波涅丁C1q/瘤坏死因子相关蛋白13 (CTRP13) 保护脏炎症和阻塞性瘤病的纤维化
Yongxia Li1,2, Wenzhe Wang2, Changxuan Liu2
1Department of Rheumatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
C1q/瘤缩因子相关蛋白13 (CTRP13) 通过抑制关键信号通路来对抗阻塞性病中的炎和纤维化. 这一发现为慢性病 (CKD) 提供了新的治疗途径.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 阻塞性病包括炎和纤维化,但机制尚不清楚.
- 目前正在调查C1q/瘤缩因子相关蛋白13 (CTRP13) 在脏疾病中的作用.
- 在纤维化患者和模型中观察到降低的CTRP13水平.
研究的目的:
- 研究CTRP13对阻塞性病中的炎和纤维化的影响.
- 阐明CTRP13作用的潜在分子机制.
- 评估CTRP13作为慢性病 (CKD) 的潜在治疗标.
主要方法:
- 建立了一个小鼠单边尿路阻塞 (UUO) 模型用于功能障碍.
- 采用了血素-氨酸染色,免疫光,西式涂抹和RT-qPCR.
- 用于重组CTRP13来评估其治疗潜力.
主要成果:
- 在纤维化患者和UUO小鼠中,CTRP13表达减少.
- CTRP13的使用逆转了UUO诱导的功能障碍,纤维化和管管损伤.
- CTRP13抑制了细胞外矩阵蛋白和促炎媒介体.
- CTRP13的保护作用与失活TGF-β/Smad和NF-κB p65通路有关.
结论:
- CTRP13在缓解脏炎症和纤维化方面发挥着至关重要的作用.
- CTRP13证明了阻塞性病和CKD的治疗潜力.
- 通过TGF-β/Smad和NF-κB通路的非激活,可以调解CTRP13的保护作用.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antihypertensive Drugs: Direct Renin Inhibitors
External Anatomy of the Kidney
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
